Please ensure Javascript is enabled for purposes of website accessibility

Oxford Professor Lowers Coronavirus Vaccine's Odds of Meeting September Deadline

By Cory Renauer – Updated May 24, 2020 at 1:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Oxford University's coronavirus vaccine project leader isn't as enthusiastic as you want him to be.

Clinical trial results from an experimental coronavirus vaccine AstraZeneca (AZN -3.21%) licensed from Oxford University might not be ready this September as hoped. In an interview with The Telegraph, the director of Oxford's Jenner Institute, Professor Adrian Hill, said the chances we'll see meaningful trial results by September are increasingly slim due to successful COVID-19 containment efforts. 

Vaccine math is hard 

In April, Prof. Hill said a million doses could be ready by September if results from ongoing efficacy tests prove ChAdOx1 nCoV-19 is safe and effective. Thanks to successful containment efforts, Hill thinks the number of new infections in the U.K. will be too few to draw any meaningful conclusions at such an early date. Out of around 10,000 people expected to enroll in the trial, the researcher expects less than 50 will catch the virus.

Microscope lenses up close

Image source: Getty Images.

While AstraZeneca can easily solve this problem by expanding the study, we still need to wait and see if new participants injected with the vaccine come down with COVID-19 less often than those randomized to receive a placebo. It's not unusual to see COVID-19 infections put healthy, athletic people in the hospital or worse. Despite popular suggestions, willingly exposing trial participants to SARS-CoV-2 to speed up the vaccine development process is unethical and illegal in at least a hundred different ways.

Recently, AstraZeneca signed an agreement to provide up to 300 million doses of ChAdOx1 nCoV-19 to the U.S. if it works as intended. The company could receive up to $1.2 billion to assist with the vaccine candidate's development, including a clinical trial expected to enroll 30,000 participants.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
$54.91 (-3.21%) $-1.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.